FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)

View source ↗

Summary

The FDA approved a supplemental Biologics License Application for BYOOVIZ (ranibizumab-nuna) from Biogen, expanding regulatory clearance for this biosimilar.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• BYOOVIZ (ranibizumab-nuna)

Snippet

SUPPL AP for BYOOVIZ (RANIBIZUMAB-NUNA)